A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis S De Vita, L Quartuccio, M Isola, C Mazzaro, P Scaini, M Lenzi, ... Arthritis & Rheumatism 64 (3), 843-853, 2012 | 470 | 2012 |
Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study X Mariette, R Seror, L Quartuccio, G Baron, S Salvin, M Fabris, ... Annals of the rheumatic diseases 74 (3), 526-531, 2015 | 356 | 2015 |
Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients C Baldini, P Pepe, L Quartuccio, R Priori, E Bartoloni, A Alunno, ... Rheumatology 53 (5), 839-844, 2014 | 283 | 2014 |
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients M Pietrogrande, S De Vita, AL Zignego, P Pioltelli, D Sansonno, S Sollima, ... Autoimmunity reviews 10 (8), 444-454, 2011 | 245 | 2011 |
Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids L Quartuccio, G Soardo, G Romano, F Zaja, CA Scott, G De Marchi, ... Rheumatology 45 (7), 842-846, 2006 | 200 | 2006 |
Preliminary classification criteria for the cryoglobulinaemic vasculitis S De Vita, F Soldano, M Isola, G Monti, A Gabrielli, A Tzioufas, C Ferri, ... Annals of the Rheumatic Diseases 70 (7), 1183-1190, 2011 | 191 | 2011 |
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data … P Brito-Zerón, N Acar-Denizli, M Zeher, A Rasmussen, R Seror, ... Annals of the rheumatic diseases 76 (6), 1042-1050, 2017 | 184 | 2017 |
BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands L Quartuccio, S Salvin, M Fabris, M Maset, E Pontarini, M Isola, S De Vita Rheumatology 52 (2), 276-281, 2013 | 184 | 2013 |
Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations P Brito-Zerón, E Theander, C Baldini, R Seror, S Retamozo, L Quartuccio, ... Expert review of clinical immunology 12 (2), 137-156, 2016 | 183 | 2016 |
Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study L Cavagna, L Nuno, CA Scire, M Govoni, FJL Longo, F Franceschini, ... Medicine 94 (32), e1144, 2015 | 180 | 2015 |
Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population‐based multicentre cohort study E Bartoloni, C Baldini, G Schillaci, L Quartuccio, R Priori, F Carubbi, V Bini, ... Journal of internal medicine 278 (2), 185-192, 2015 | 174 | 2015 |
Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study L Quartuccio, M Isola, C Baldini, R Priori, EB Bocci, F Carubbi, M Maset, ... Journal of autoimmunity 51, 75-80, 2014 | 174 | 2014 |
How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project) P Brito-Zerón, N Acar-Denizli, WF Ng, M Zeher, A Rasmussen, T Mandl, ... Clinical and experimental rheumatology 36 (3), S102-S112, 2018 | 173 | 2018 |
COVID 19: a clue from innate immunity D Birra, M Benucci, L Landolfi, A Merchionda, G Loi, P Amato, G Licata, ... Immunologic research 68, 161-168, 2020 | 168 | 2020 |
Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course L Cavagna, E Trallero-Araguás, F Meloni, I Cavazzana, J Rojas-Serrano, ... Journal of clinical medicine 8 (11), 2013, 2019 | 167 | 2019 |
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care L Quartuccio, A Sonaglia, D McGonagle, M Fabris, M Peghin, D Pecori, ... Journal of Clinical Virology 129, 104444, 2020 | 163 | 2020 |
Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study S De Vita, L Quartuccio, R Seror, S Salvin, P Ravaud, M Fabris, ... Rheumatology 54 (12), 2249-2256, 2015 | 155 | 2015 |
Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives M Infantino, A Damiani, FL Gobbi, V Grossi, B Lari, D Macchia, P Casprini, ... Israel Medical Association Journal 22 (4), 203-210, 2020 | 153 | 2020 |
B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection M Fabris, L Quartuccio, S Sacco, G De Marchi, G Pozzato, C Mazzaro, ... Rheumatology 46 (1), 37-43, 2007 | 144 | 2007 |
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in … L Quartuccio, M Fabris, S Salvin, F Atzeni, M Saracco, M Benucci, ... Rheumatology 48 (12), 1557-1559, 2009 | 135 | 2009 |